The Review28m
Sixth Court of Appeals weighing bond motions
The question of a requirement bond for residents appealing the $600 million settlement between those impacted by the 2023 train derailment and Norfolk Southern is still up the air, as attorneys for ...
FiercePharma1d
Gearing up to challenge Lilly in obesity, Kailera picks Zepbound brand leader as new commercial chief
The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...
JD Supra1d
The GLP-1 Saga Continues: FDA Ends the Tirzepatide Shortage: Frequently Asked Questions
FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...
Residents ordered to pay $850,000 bond to appeal Ohio derailment settlement vow not to give up
The residents who question whether Norfolk Southern's $600 million settlement offers enough compensation for the East ...
Morningstar14d
Eli Lilly: Weak Preliminary Sales for Mounjaro and Zepbound; Shares Remain Overvalued
Why it matters: Lilly's growth prospects are driven by Mounjaro and Zepbound, and shortfalls in sales could portend weaker long-term potential for this market. Lilly is positioned to remain the ...
Yahoo14d
Eli Lilly’s Zepbound and Mounjaro Sales Missed Estimates Again. The Wobble’s Looking Serious.
Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the second consecutive miss for the two closely watched ...
Yahoo Finance14d
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...
NBC Connecticut14d
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly expects about $3.5 billion in revenue for its diabetes treatment Mounjaro and $1.9 billion for its obesity drug Zepbound. CEO Dave Ricks told CNBC that the company has "tons of supply ...
Morningstar14d
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria Bioscience ...
AOL14d
Eli Lilly stock tumbles after new forecasts show weight-loss drug sales grow slower than expected
Lilly expects its most-watched blockbuster products — GLP-1 tirzepatide products Mounjaro and Zepbound — to miss consensus as well. Guidance for diabetes drug Mounjaro is $3.5 billion ...
U.S. News & World Report14d
Lilly Shares on Track for Worst Day Since 2021 After Downbeat Zepbound Sales Forecast
(Reuters) -Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates, marking the second time sales have disappointed ...
Stockhouse15d
Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)
Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable to injected Zepbound® KELOWNA, BC / ACCESSWIRE / January 14, 2025 / Lexaria ...